Real-world treatment patterns and outcomes among patients initiating sequential regorafenib and trifluridine/tipiracil ± bevacizumab in patients with metastatic colorectal cancer in a US community setting (SEQRT2)
Treatment sequence numerically favored R-T and provided an additional survival benefit of 2.6 months in this cohort, although this was not statistically significant. Providing access to regorafenib and FTD/TPI ± bevacizumab is critical to maximizing patient benefit and optimizing patient care in advanced stages of mCRC.
Authors
- Svetlana Babajanyan (ORCID: https://orcid.org/0000-0002-5910-5988)
- David Cosgrove (ORCID: https://orcid.org/0000-0003-2700-5656)
- Ila Sruti
- Brian Hocum
- Junxin Shi
- Tanios Bekaii‐Saab (ORCID: https://orcid.org/0000-0001-7721-1699)
- Gregory Patton
- Sreevalsa Appukkuttan (ORCID: https://orcid.org/0000-0003-2537-1687)
- Wei D (ORCID: https://orcid.org/0000-0003-2014-1559)
- Arvind Katta
Institutions
- Bayer (United States) (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- The US Oncology Network (US)
- Diagnostics for the Real World (United States) (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.3389/fonc.2025.1591245
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Comprehensive Cancer Network